Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

Weitere Dokumente

SML2419

Sigma-Aldrich

GSK690

≥98% (HPLC)

Synonym(e):

(R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl) benzonitrile), (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-p-tolylpyridin-3-yl)benzonitrile, 4-(2-(4-Methylphenyl)-5-((3R)-3-pyrrolidinylmethoxy)-3-pyridinyl)benzonitrile, GSK 354, GSK 690, GSK-354, GSK-690, GSK354

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C24H23N3O
CAS-Nummer:
2101305-84-2
Molekulargewicht:
369.46
UNSPSC-Code:
12352200

Assay

≥98% (HPLC)

Form

powder

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL, clear

Lagertemp.

2-8°C

SMILES String

N#CC1=CC=C(C2=CC(OC[C@H]3CNCC3)=CN=C2C4=CC=C(C)C=C4)C=C1

Biochem./physiol. Wirkung

GSK690 (GSK354) is a cell-permeable pyrrolidinylmethoxypyridine-based compound that inhibits lysine-specific demethylase 1 (LSD1; KDM1A) in a potent and reversible manner (IC50 = 90 nM) without affecting MAO-A activity (IC50 >200 μM). GSK690 is shown to induce the expressions of CD86 (EC50 = 1.4 μM in THP1 cells) and LY96 (EC50 = 423 nM in MV4-11 cells), and prevent adipogenesis in murine preadipocyte cultures.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Alba Maiques-Diaz et al.
Cell reports, 22(13), 3641-3659 (2018-03-29)
Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leukemia (AML) with MLL translocations. The assumption has been that differentiation is induced through blockade of LSD1's histone demethylase activity. However, we observed that rapid, extensive, drug-induced changes in transcription occurred
Daniel P Mould et al.
Journal of medicinal chemistry, 60(19), 7984-7999 (2017-09-12)
Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML). Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clinical trials; however, the development of effective
Tinka Haydn et al.
Cell death & disease, 8(6), e2879-e2879 (2017-06-16)
The lysine-specific demethylase 1 (LSD1) is overexpressed in several cancers including rhabdomyosarcoma (RMS). However, little is yet known about whether or not LSD1 may serve as therapeutic target in RMS. We therefore investigated the potential of LSD1 inhibitors alone or
Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments
Hitchin JR, Blagg J, Burke R .
Medicinal Chemistry, 1513-1522 (2013)
Delphine Duteil et al.
Nature communications, 5, 4093-4093 (2014-06-11)
Exposure to environmental cues such as cold or nutritional imbalance requires white adipose tissue (WAT) to adapt its metabolism to ensure survival. Metabolic plasticity is prominently exemplified by the enhancement of mitochondrial biogenesis in WAT in response to cold exposure
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.